Tine Kold Olesen

MSc, Exec. MBA

Role in PharmNovo: Business advisor.

Born: 1963.

Education: MSc in Pharmacy from Copenhagen University in 1992, DK; Exec. MBA from Imperial College, London, UK in 2012.

Work experience: Tine is currently based in US and has 25 years of experience in pharmaceutical industry. She has worked at Ferring Pharmaceuticals in US and in Denmark for the past 18 years where she directs integrated clinical development programs from early stage to life cycle management in uro-/oncology with responsibility for the design and development of novel strategies from early stage and through marketing authorization, followed by market access in R&D. Her key focus is within CMC and clinical development, directing regulatory actions, including NDA submissions and FDA advisory committee, interpretation of scientific data, building the value story and development of new businesses. Tine has prior experience in the therapeutic fields of Parkinson’s disease, epilepsy, diabetes, and migraine headaches within large pharma companies (Novo, GSK, and Orion).

Member of:

Business advisors

Latest news

View all

PharmNovo live at neurology theme event at RedEye

October 25, 2024

PharmNovo live at neurology theme event at RedEye

Per von Mentzer, CEO, presented PN6047 at the Neurology Event at RedEye on October 23. Take the opportunity to listen to a very interesting live presentation and learn more about PN6047, the unique first-in-class phase II ready asset with break-through potential in treatment of neuropathic pain. PN6047 demonstrates safety and tolerability and a lack of the adverse effects commonly associated with conventional opioids. These findings suggest a promising path forward in the field of pain management.

October 10, 2024

PharmNovo at the LSX Nordic Congress

PharmNovo attended the LSX Nordic Congress in Copenhagen 8-9 October and Per von Mentzer, CEO presented PN6047, a unique first-in-class phase II ready asset with break-through potential in treatment of neuropathic pain. Being one of 68 companies that have recently been awarded by EIC for up to 17.5 MEUR (2.5 MEUR grant and up to 15 MEUR equity) from a total of 969 applicants is a strong validation of the potential of the phase II ready asset PN6047 and of PharmNovo. Take the opportunity to listen to the presentation here:

July 17, 2024

17.5 MEUR blended funding from EIC

PharmNovo is very pleased to announce that we have been awarded a 2.5 MEUR grant and an opportunity for up to 15 MEUR equity investment from the European Innovation Council (EIC) for innovative pain treatment. The equity part being contingent on investments of equal amounts from co-investors.

PharmNovo presenting at the Global Forum

June 5, 2024

PharmNovo presenting at the Global Forum

On May 29–30, BioStock hosted the Global Forum. The event is the first of its kind, aimed at bringing together growth stage Nordic life science companies looking to expand into new markets and experts armed with a profound knowledge of how business is done across the globe.